J G Klign, H J de Voogt, F H Schröder, F H de Jong. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Buserelin/administration & dosageCyproterone/administration & dosageDrug Therapy, CombinationHumansMaleProstatic Neoplasms/drug therapyProstatic Neoplasms/secondary
Substances: See more » CyproteroneBuserelin
Year: 1985 PMID: 2863504 DOI: 10.1016/s0140-6736(85)90415-5
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321